HU-308, a synthetic cannabinoid has demonstrated in vivo anti-osteoporotic efficacy of agonist highly specific for CB2 that concomitantly restrains bone resorption and stimulates bone formation. HU-308 has no psychotropic or anti-annorexigenic...

HU-308, a synthetic cannabinoid has demonstrated in vivo anti-osteoporotic efficacy of agonist highly specific for CB2 that concomitantly restrains bone resorption and stimulates bone formation. HU-308 has no psychotropic or anti-annorexigenic activities and is orally bioavailable (Fatty-acid-derived therapy for osteoporosis and other skeletal deficits deficits)
Cannabinoid agonist restrains bone resorption and stimulates bone formation

Categories

Bone formation, osteoporosis, agonist for peripheral cannabinoid receptor

Development Stage

In vivo proof of principle; expanded pre-clinical experiments

Patent Status

Patent application at national phase

Market Size

Currently, the osteoporosis drug market is worth $10.0 billion

Highlights

*

Osteoporosis is characterized by an imbalance between bone formation and resorption resulting in net bone loss and increased susceptibility to fractures
*

Most anti-osteoporotic drugs in clinical use, such as bisphosphonates, estrogen, and calcitonin are anti-resorptive and used mainly to prevent postmenopausal bone loss.
*

Signaling of the peripheral cannabinoid receptor (CB2) is involved in the regulation of bone remodelling, slowing down bone loss.

Our Innovation

*
A synthetic cannabinoid agonist highly, which is specific for CB2 and therefore not psychoactive, inhibits bone resorption and stimulates bone formation.

Key Features

*
Attenuates and reverses bone loss: restores bone mass and architecture.
*
No psychotropic or anti-annorexigenic activities

Development Milestones

*
Further development of this treatment involves the standard path, e.g., toxicology, mutagenesis, in vivo pharmacology, stability studies and clinical trials

The Opportunity

*
Osteoporosis is the most prevalent degenerative disease in developed countries. The number of patients is expected to increase to 50 million in 2015.
*
The global market for bisphosphonates, the most commonly prescribed class of drugs for the prevention and treatment of osteoporosis, is approaching $10 billion and is growing rapidly.

project-id 6-2006-229

 

Preclinical

Patent application at national phase